Akero Therapeutics Announces Publication of Phase 2b SYMMETRY Trial in the New England Journal of Medicine
Provided By GlobeNewswire
Last update: May 9, 2025
Results support potential benefit of efruxifermin (EFX) to elicit fibrosis improvement in patients with compensated cirrhosis (F4 fibrosis) due to MASH 96-week data from SYMMETRY trial presented at EASL Congress 2025
Read more at globenewswire.com47.03
-2.2 (-4.47%)
Find more stocks in the Stock Screener
AKRO Latest News and Analysis
